| Title: |
Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer |
| Authors: |
Blinman, Prunella; Martin, Andrew; Jefford, Michael; Goldstein, David; Boadle, David; Morris, Michelle; Tebbutt, Niall; Aiken, Christine; Harkin, Andrea; Segelov, Eva; Haydon, Andrew; Iveson, Tim; Stockler, Martin R |
| Source: |
urn:ISSN:2515-5091 ; JNCI CANCER SPECTRUM, 5, 1 |
| Publisher Information: |
Oxford University Press |
| Publication Year: |
2021 |
| Collection: |
UNSW Sydney (The University of New South Wales): UNSWorks |
| Subject Terms: |
32 Biomedical and Clinical Sciences; 3211 Oncology and Carcinogenesis; Cancer; Clinical Trials and Supportive Activities; Colo-Rectal Cancer; Digestive Diseases; Clinical Research; 6.1 Pharmaceuticals; 3 Good Health and Well Being; Antineoplastic Combined Chemotherapy Protocols; Australia; Capecitabine; Chemotherapy; Adjuvant; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Life Expectancy; Male; Middle Aged; New Zealand; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Patient Preference; Prospective Studies; Surveys and Questionnaires |
| Description: |
Background SCOT was an international, randomized phase 3 trial of 3 months vs 6 months of adjuvant chemotherapy with oxaliplatin and a fluoropyrimidine in patients with colorectal cancer. We sought patients’ preferences for 3 months vs 6 months of adjuvant chemotherapy in the SCOT trial. Methods SCOT participants from Australia and New Zealand completed a validated questionnaire (at 3 and 18 months) to elicit the minimum survival benefits judged necessary to make an extra 3 months of adjuvant chemotherapy worthwhile, based on their experience. Standardized hypothetical scenarios used the following baseline survivals (with 3 months of chemotherapy): life expectancies (LE) of 5 years and 15 years and 5-year survival rates (5YS) of 65% and 85%. Results Of the 160 participants, 82 were assigned 3 months adjuvant chemotherapy, and 78 were assigned 6 months. Adjuvant chemotherapy was FOLFOX in 121 (75.6%) and XELOX in 39 (24.4%). Preferences varied substantially and did not differ according to treatment group. The median survival benefits judged necessary to make the extra 3 months of chemotherapy worthwhile were an extra 3 years beyond a LE of 5 years; 3 years beyond a LE of 15 years; 15% beyond a 5YS of 65%; and 5% beyond a 5YS of 85%. Preferences were similar at 3 months and 18 months. Preferences were not predicted by participants’ baseline characteristics. Conclusion Preferences varied substantially, and the benefits many required to warrant an extra 3 months of adjuvant chemotherapy were larger than the benefits of an extra 3 months of chemotherapy calculated in the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) meta-analysis. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
unknown |
| Relation: |
https://hdl.handle.net/1959.4/unsworks_79381; https://doi.org/10.1093/jncics/pkaa107 |
| DOI: |
10.1093/jncics/pkaa107 |
| Availability: |
https://hdl.handle.net/1959.4/unsworks_79381; https://unsworks.unsw.edu.au/bitstreams/c9bed9f8-5a01-43b3-94c4-efdbd1c47dcf/download; https://doi.org/10.1093/jncics/pkaa107 |
| Rights: |
open access ; https://purl.org/coar/access_right/c_abf2 ; CC BY-NC-ND ; https://creativecommons.org/licenses/by-nc-nd/4.0/ ; free_to_read ; © The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| Accession Number: |
edsbas.B438F841 |
| Database: |
BASE |